Eric Joel Tchetgen Tchetgen, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Causality | 31 | 2024 | 1242 | 4.280 |
Why?
|
Models, Statistical | 37 | 2024 | 5079 | 3.680 |
Why?
|
Data Interpretation, Statistical | 27 | 2024 | 2691 | 3.530 |
Why?
|
Epidemiologic Research Design | 10 | 2018 | 368 | 2.310 |
Why?
|
Selection Bias | 8 | 2024 | 359 | 1.840 |
Why?
|
Regression Analysis | 11 | 2017 | 6345 | 1.380 |
Why?
|
Mendelian Randomization Analysis | 7 | 2024 | 1007 | 1.150 |
Why?
|
Odds Ratio | 10 | 2023 | 9647 | 1.150 |
Why?
|
Statistics as Topic | 5 | 2021 | 2358 | 1.040 |
Why?
|
Computer Simulation | 19 | 2024 | 6241 | 0.960 |
Why?
|
Proportional Hazards Models | 14 | 2022 | 12463 | 0.840 |
Why?
|
Propensity Score | 2 | 2024 | 1913 | 0.780 |
Why?
|
Circumcision, Male | 2 | 2020 | 148 | 0.780 |
Why?
|
Survival Analysis | 6 | 2019 | 10090 | 0.710 |
Why?
|
Probability | 3 | 2018 | 2477 | 0.700 |
Why?
|
Pneumococcal Vaccines | 1 | 2024 | 397 | 0.700 |
Why?
|
Friends | 1 | 2021 | 149 | 0.690 |
Why?
|
Epidemiologic Methods | 3 | 2015 | 1336 | 0.690 |
Why?
|
Influenza Vaccines | 4 | 2021 | 768 | 0.680 |
Why?
|
HIV Infections | 19 | 2023 | 17354 | 0.670 |
Why?
|
Likelihood Functions | 6 | 2020 | 992 | 0.570 |
Why?
|
Patient Compliance | 3 | 2023 | 2690 | 0.560 |
Why?
|
Research Design | 3 | 2022 | 6180 | 0.550 |
Why?
|
Employment | 1 | 2022 | 1118 | 0.530 |
Why?
|
Survivors | 2 | 2018 | 2371 | 0.510 |
Why?
|
Activities of Daily Living | 2 | 2023 | 2421 | 0.510 |
Why?
|
Peer Group | 1 | 2021 | 692 | 0.510 |
Why?
|
Botswana | 7 | 2020 | 1048 | 0.500 |
Why?
|
Biometry | 3 | 2024 | 563 | 0.500 |
Why?
|
Influenza, Human | 4 | 2021 | 1521 | 0.490 |
Why?
|
Longitudinal Studies | 12 | 2023 | 14608 | 0.490 |
Why?
|
Case-Control Studies | 7 | 2019 | 22176 | 0.480 |
Why?
|
Logistic Models | 9 | 2017 | 13255 | 0.480 |
Why?
|
Income | 2 | 2022 | 1877 | 0.470 |
Why?
|
Opportunistic Infections | 1 | 2017 | 376 | 0.460 |
Why?
|
Hazardous Substances | 1 | 2015 | 153 | 0.460 |
Why?
|
Osteoporosis, Postmenopausal | 1 | 2017 | 396 | 0.450 |
Why?
|
Environmental Exposure | 4 | 2014 | 4485 | 0.450 |
Why?
|
Humans | 113 | 2024 | 761596 | 0.430 |
Why?
|
Patient Dropouts | 2 | 2012 | 412 | 0.430 |
Why?
|
Mothers | 1 | 2023 | 2198 | 0.410 |
Why?
|
Aldehyde Dehydrogenase | 1 | 2013 | 146 | 0.400 |
Why?
|
Stillbirth | 1 | 2015 | 368 | 0.400 |
Why?
|
Live Birth | 1 | 2015 | 511 | 0.380 |
Why?
|
Randomized Controlled Trials as Topic | 9 | 2021 | 10212 | 0.380 |
Why?
|
Fetal Growth Retardation | 1 | 2015 | 580 | 0.380 |
Why?
|
Linear Models | 7 | 2018 | 5872 | 0.370 |
Why?
|
Anti-HIV Agents | 4 | 2020 | 4527 | 0.340 |
Why?
|
Bone Density Conservation Agents | 1 | 2017 | 795 | 0.340 |
Why?
|
Medication Adherence | 2 | 2019 | 2176 | 0.320 |
Why?
|
Pregnancy Outcome | 2 | 2017 | 2922 | 0.320 |
Why?
|
Clinical Trials as Topic | 2 | 2023 | 8002 | 0.320 |
Why?
|
Vaccines | 3 | 2012 | 844 | 0.320 |
Why?
|
Sensitivity and Specificity | 5 | 2016 | 14665 | 0.310 |
Why?
|
HIV-1 | 4 | 2020 | 6863 | 0.300 |
Why?
|
Self-Assessment | 1 | 2010 | 397 | 0.300 |
Why?
|
Viral Load | 6 | 2020 | 3332 | 0.300 |
Why?
|
Sexually Transmitted Diseases | 1 | 2014 | 662 | 0.300 |
Why?
|
Models, Theoretical | 2 | 2022 | 3575 | 0.300 |
Why?
|
Antibodies, Viral | 1 | 2019 | 3156 | 0.290 |
Why?
|
Housing | 3 | 2018 | 670 | 0.290 |
Why?
|
Anticonvulsants | 1 | 2017 | 1906 | 0.280 |
Why?
|
Vaccination | 3 | 2021 | 3384 | 0.280 |
Why?
|
Pregnancy Complications, Infectious | 2 | 2017 | 2151 | 0.280 |
Why?
|
Residence Characteristics | 4 | 2018 | 2095 | 0.270 |
Why?
|
Ovarian Neoplasms | 3 | 2019 | 4878 | 0.260 |
Why?
|
Smoking | 8 | 2024 | 9053 | 0.260 |
Why?
|
Cohort Studies | 12 | 2020 | 41495 | 0.250 |
Why?
|
Memory Disorders | 3 | 2017 | 1199 | 0.250 |
Why?
|
Occupational Exposure | 2 | 2015 | 1813 | 0.250 |
Why?
|
Antiretroviral Therapy, Highly Active | 4 | 2020 | 1897 | 0.250 |
Why?
|
Genetic Predisposition to Disease | 6 | 2019 | 17904 | 0.240 |
Why?
|
Epidemiologic Studies | 2 | 2018 | 675 | 0.230 |
Why?
|
Biostatistics | 2 | 2018 | 164 | 0.230 |
Why?
|
Anti-Retroviral Agents | 3 | 2019 | 1784 | 0.230 |
Why?
|
Poverty | 4 | 2018 | 2697 | 0.230 |
Why?
|
Female | 50 | 2024 | 392705 | 0.210 |
Why?
|
Air Pollution | 1 | 2017 | 2359 | 0.210 |
Why?
|
Pregnancy Complications | 1 | 2017 | 2947 | 0.210 |
Why?
|
New Jersey | 1 | 2022 | 295 | 0.200 |
Why?
|
Depression | 5 | 2022 | 8126 | 0.200 |
Why?
|
Quality of Life | 1 | 2023 | 13367 | 0.200 |
Why?
|
Models, Structural | 1 | 2022 | 340 | 0.190 |
Why?
|
Models, Genetic | 2 | 2015 | 3442 | 0.190 |
Why?
|
Observation | 2 | 2016 | 310 | 0.190 |
Why?
|
Epilepsy | 1 | 2017 | 3290 | 0.190 |
Why?
|
Phobic Disorders | 2 | 2014 | 439 | 0.190 |
Why?
|
South Africa | 2 | 2023 | 1843 | 0.190 |
Why?
|
Educational Status | 3 | 2017 | 2522 | 0.180 |
Why?
|
Disabled Persons | 1 | 2010 | 1226 | 0.180 |
Why?
|
Cognition Disorders | 4 | 2017 | 3980 | 0.170 |
Why?
|
Seroepidemiologic Studies | 1 | 2021 | 397 | 0.170 |
Why?
|
Treatment Outcome | 8 | 2024 | 64685 | 0.170 |
Why?
|
Alcohol Drinking | 1 | 2013 | 4028 | 0.170 |
Why?
|
Brazil | 1 | 2024 | 1230 | 0.170 |
Why?
|
Zambia | 2 | 2018 | 262 | 0.170 |
Why?
|
Hemagglutination Inhibition Tests | 1 | 2019 | 85 | 0.170 |
Why?
|
Dementia | 6 | 2017 | 2689 | 0.160 |
Why?
|
Influenza B virus | 1 | 2019 | 52 | 0.160 |
Why?
|
Genome-Wide Association Study | 4 | 2016 | 12690 | 0.160 |
Why?
|
Health Status Disparities | 1 | 2010 | 1853 | 0.160 |
Why?
|
Health Surveys | 4 | 2018 | 4061 | 0.160 |
Why?
|
Mass Screening | 3 | 2020 | 5429 | 0.160 |
Why?
|
Policy | 1 | 2022 | 509 | 0.160 |
Why?
|
Pregnancy | 6 | 2024 | 29890 | 0.160 |
Why?
|
Vaccines, Inactivated | 1 | 2019 | 179 | 0.160 |
Why?
|
Prevalence | 5 | 2022 | 15733 | 0.160 |
Why?
|
Reimbursement, Incentive | 1 | 2023 | 543 | 0.150 |
Why?
|
Cluster Analysis | 2 | 2016 | 2707 | 0.140 |
Why?
|
Control Groups | 1 | 2017 | 104 | 0.140 |
Why?
|
Incidence | 8 | 2022 | 21355 | 0.140 |
Why?
|
Adolescent | 14 | 2024 | 88326 | 0.140 |
Why?
|
Male | 40 | 2023 | 360846 | 0.140 |
Why?
|
Algorithms | 6 | 2018 | 14033 | 0.140 |
Why?
|
Nigeria | 1 | 2019 | 770 | 0.140 |
Why?
|
Disease Transmission, Infectious | 2 | 2012 | 560 | 0.130 |
Why?
|
Middle Aged | 29 | 2023 | 220921 | 0.130 |
Why?
|
Cardiovascular Diseases | 3 | 2020 | 15502 | 0.130 |
Why?
|
Epidemics | 1 | 2022 | 512 | 0.130 |
Why?
|
Aging | 4 | 2023 | 8710 | 0.130 |
Why?
|
Mortality | 2 | 2018 | 2902 | 0.130 |
Why?
|
Education, Nonprofessional | 1 | 2015 | 31 | 0.130 |
Why?
|
Environmental Health | 1 | 2018 | 290 | 0.130 |
Why?
|
Epidemiologic Measurements | 1 | 2015 | 23 | 0.130 |
Why?
|
Markov Chains | 3 | 2013 | 966 | 0.120 |
Why?
|
Anticipation, Psychological | 1 | 2016 | 85 | 0.120 |
Why?
|
Orthomyxoviridae | 1 | 2016 | 149 | 0.120 |
Why?
|
Drug Evaluation | 1 | 2016 | 641 | 0.120 |
Why?
|
Biomedical Research | 1 | 2010 | 3429 | 0.120 |
Why?
|
Aged | 23 | 2023 | 169310 | 0.120 |
Why?
|
Uranium | 1 | 2014 | 24 | 0.120 |
Why?
|
Nevirapine | 1 | 2015 | 273 | 0.120 |
Why?
|
Cognition | 4 | 2021 | 6992 | 0.120 |
Why?
|
Disease Outbreaks | 1 | 2023 | 1749 | 0.110 |
Why?
|
Risk | 3 | 2017 | 9610 | 0.110 |
Why?
|
Mining | 1 | 2014 | 93 | 0.110 |
Why?
|
Risk Factors | 15 | 2022 | 74213 | 0.110 |
Why?
|
Zidovudine | 1 | 2015 | 624 | 0.110 |
Why?
|
Pharmacoepidemiology | 1 | 2017 | 350 | 0.110 |
Why?
|
Receptors, Vasopressin | 1 | 2013 | 106 | 0.110 |
Why?
|
Calibration | 1 | 2016 | 818 | 0.110 |
Why?
|
Treatment Failure | 1 | 2019 | 2643 | 0.110 |
Why?
|
Family Characteristics | 2 | 2016 | 1004 | 0.110 |
Why?
|
Receptors, Oxytocin | 1 | 2013 | 69 | 0.110 |
Why?
|
HIV | 1 | 2020 | 1582 | 0.110 |
Why?
|
Aged, 80 and over | 13 | 2017 | 58984 | 0.100 |
Why?
|
Bayes Theorem | 2 | 2018 | 2330 | 0.100 |
Why?
|
Coronary Disease | 2 | 2017 | 5914 | 0.100 |
Why?
|
Sampling Studies | 1 | 2014 | 615 | 0.100 |
Why?
|
Phenotype | 1 | 2010 | 16592 | 0.100 |
Why?
|
Young Adult | 12 | 2023 | 59260 | 0.100 |
Why?
|
Meta-Analysis as Topic | 1 | 2017 | 1380 | 0.100 |
Why?
|
Infant, Small for Gestational Age | 1 | 2015 | 461 | 0.100 |
Why?
|
Osteoporotic Fractures | 1 | 2017 | 411 | 0.100 |
Why?
|
Diphosphonates | 1 | 2017 | 635 | 0.100 |
Why?
|
Databases, Factual | 2 | 2018 | 7968 | 0.100 |
Why?
|
Proxy | 1 | 2013 | 151 | 0.100 |
Why?
|
Uncertainty | 1 | 2017 | 754 | 0.100 |
Why?
|
Stress, Psychological | 2 | 2018 | 4481 | 0.100 |
Why?
|
Stroke | 4 | 2022 | 9758 | 0.100 |
Why?
|
RNA, Viral | 2 | 2018 | 2846 | 0.100 |
Why?
|
Liver Failure | 1 | 2013 | 250 | 0.100 |
Why?
|
Adult | 22 | 2023 | 221210 | 0.100 |
Why?
|
Body Mass Index | 5 | 2024 | 12953 | 0.100 |
Why?
|
Temperature | 1 | 2018 | 2226 | 0.100 |
Why?
|
Diabetes Mellitus, Type 2 | 4 | 2018 | 12149 | 0.090 |
Why?
|
Obesity | 4 | 2021 | 12947 | 0.090 |
Why?
|
Israel | 1 | 2013 | 726 | 0.090 |
Why?
|
Social Class | 2 | 2017 | 2004 | 0.090 |
Why?
|
Genetic Markers | 2 | 2014 | 2601 | 0.090 |
Why?
|
Chromosomes, Human, Pair 15 | 1 | 2012 | 361 | 0.090 |
Why?
|
Risk Reduction Behavior | 1 | 2017 | 1112 | 0.090 |
Why?
|
Depressive Disorder, Major | 2 | 2018 | 4762 | 0.090 |
Why?
|
United States | 10 | 2024 | 72340 | 0.080 |
Why?
|
Infant, Newborn | 2 | 2023 | 26202 | 0.080 |
Why?
|
Nasopharynx | 1 | 2012 | 401 | 0.080 |
Why?
|
Drug Administration Schedule | 1 | 2017 | 4853 | 0.080 |
Why?
|
Albuminuria | 1 | 2013 | 658 | 0.080 |
Why?
|
Monte Carlo Method | 1 | 2014 | 1258 | 0.080 |
Why?
|
BRCA2 Protein | 1 | 2013 | 805 | 0.080 |
Why?
|
Crime Victims | 1 | 2013 | 347 | 0.080 |
Why?
|
Epistasis, Genetic | 1 | 2010 | 352 | 0.080 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2012 | 445 | 0.080 |
Why?
|
Diabetes Mellitus | 3 | 2017 | 5841 | 0.080 |
Why?
|
Risk-Taking | 1 | 2014 | 1038 | 0.080 |
Why?
|
Analysis of Variance | 2 | 2014 | 6228 | 0.080 |
Why?
|
Lead | 1 | 2014 | 879 | 0.070 |
Why?
|
Follow-Up Studies | 7 | 2017 | 39106 | 0.070 |
Why?
|
Amyloid beta-Peptides | 1 | 2021 | 3839 | 0.070 |
Why?
|
Alzheimer Disease | 2 | 2021 | 8601 | 0.070 |
Why?
|
Occupational Diseases | 1 | 2015 | 1490 | 0.070 |
Why?
|
Social Support | 1 | 2017 | 2172 | 0.070 |
Why?
|
Polymorphism, Genetic | 2 | 2014 | 4243 | 0.070 |
Why?
|
Social Behavior | 1 | 2013 | 1135 | 0.070 |
Why?
|
Polymorphism, Single Nucleotide | 4 | 2015 | 15936 | 0.070 |
Why?
|
Streptococcus pneumoniae | 1 | 2012 | 730 | 0.070 |
Why?
|
Particulate Matter | 1 | 2018 | 2605 | 0.070 |
Why?
|
Body Weight | 1 | 2017 | 4618 | 0.070 |
Why?
|
Multifactorial Inheritance | 1 | 2014 | 1387 | 0.070 |
Why?
|
Cross-Sectional Studies | 4 | 2020 | 26129 | 0.060 |
Why?
|
Health Behavior | 1 | 2017 | 2644 | 0.060 |
Why?
|
Attitude to Health | 1 | 2014 | 2025 | 0.060 |
Why?
|
Lung Neoplasms | 3 | 2014 | 13381 | 0.060 |
Why?
|
Confidence Intervals | 1 | 2010 | 2927 | 0.060 |
Why?
|
Environment | 1 | 2010 | 1123 | 0.060 |
Why?
|
Environmental Pollutants | 1 | 2014 | 1277 | 0.060 |
Why?
|
Sex Factors | 5 | 2016 | 10554 | 0.060 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2013 | 1899 | 0.060 |
Why?
|
Estrogens | 1 | 2010 | 1522 | 0.060 |
Why?
|
Health Status | 1 | 2016 | 4077 | 0.050 |
Why?
|
Hepatitis C | 1 | 2013 | 1584 | 0.050 |
Why?
|
Rural Population | 3 | 2019 | 2287 | 0.050 |
Why?
|
Age Factors | 4 | 2016 | 18399 | 0.050 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2015 | 2223 | 0.050 |
Why?
|
Comorbidity | 1 | 2017 | 10508 | 0.050 |
Why?
|
Communicable Diseases | 1 | 2010 | 875 | 0.050 |
Why?
|
Socioeconomic Factors | 2 | 2019 | 7828 | 0.050 |
Why?
|
Time Factors | 5 | 2017 | 39969 | 0.050 |
Why?
|
Child | 6 | 2024 | 80158 | 0.050 |
Why?
|
Genomics | 2 | 2015 | 5821 | 0.050 |
Why?
|
Nutrition Surveys | 1 | 2009 | 1733 | 0.050 |
Why?
|
Blood Pressure | 1 | 2017 | 8481 | 0.050 |
Why?
|
Endometrial Neoplasms | 1 | 2010 | 1366 | 0.050 |
Why?
|
Random Allocation | 2 | 2016 | 2395 | 0.040 |
Why?
|
Multivariate Analysis | 1 | 2014 | 12059 | 0.040 |
Why?
|
Risk Assessment | 3 | 2015 | 23996 | 0.040 |
Why?
|
Retrospective Studies | 4 | 2017 | 80647 | 0.040 |
Why?
|
CD4 Lymphocyte Count | 2 | 2015 | 2571 | 0.040 |
Why?
|
Comparative Effectiveness Research | 1 | 2024 | 709 | 0.040 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2013 | 3415 | 0.040 |
Why?
|
Delivery of Health Care | 1 | 2016 | 5337 | 0.040 |
Why?
|
Influenza A virus | 1 | 2021 | 458 | 0.040 |
Why?
|
HIV Antigens | 1 | 2018 | 325 | 0.040 |
Why?
|
Neoplasms | 2 | 2017 | 22173 | 0.040 |
Why?
|
Breast Neoplasms | 3 | 2017 | 21019 | 0.040 |
Why?
|
Neuropsychological Tests | 3 | 2015 | 7054 | 0.030 |
Why?
|
Cities | 1 | 2018 | 546 | 0.030 |
Why?
|
Genotype | 3 | 2015 | 12990 | 0.030 |
Why?
|
India | 2 | 2013 | 2348 | 0.030 |
Why?
|
Single Person | 1 | 2014 | 31 | 0.030 |
Why?
|
Poverty Areas | 1 | 2016 | 263 | 0.030 |
Why?
|
Widowhood | 1 | 2014 | 51 | 0.030 |
Why?
|
Phylogeny | 1 | 2022 | 2811 | 0.030 |
Why?
|
Receptor, Melanocortin, Type 4 | 1 | 2014 | 129 | 0.030 |
Why?
|
Marital Status | 1 | 2014 | 426 | 0.030 |
Why?
|
Marriage | 1 | 2014 | 351 | 0.030 |
Why?
|
Terminology as Topic | 1 | 2020 | 1530 | 0.030 |
Why?
|
Family | 1 | 2023 | 3195 | 0.030 |
Why?
|
Microbial Interactions | 1 | 2012 | 74 | 0.020 |
Why?
|
Specimen Handling | 1 | 2016 | 702 | 0.020 |
Why?
|
Serotyping | 1 | 2012 | 325 | 0.020 |
Why?
|
HIV Antibodies | 1 | 2018 | 1303 | 0.020 |
Why?
|
HIV Protease Inhibitors | 1 | 2014 | 432 | 0.020 |
Why?
|
Genetic Fitness | 1 | 2012 | 115 | 0.020 |
Why?
|
Continuity of Patient Care | 1 | 2018 | 1069 | 0.020 |
Why?
|
Social Isolation | 1 | 2013 | 364 | 0.020 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2014 | 549 | 0.020 |
Why?
|
Reproducibility of Results | 3 | 2014 | 20100 | 0.020 |
Why?
|
Interpersonal Relations | 1 | 2017 | 1436 | 0.020 |
Why?
|
Evaluation Studies as Topic | 1 | 2012 | 1625 | 0.020 |
Why?
|
Kenya | 1 | 2012 | 758 | 0.020 |
Why?
|
Hospitalization | 2 | 2024 | 10721 | 0.020 |
Why?
|
Sex Distribution | 1 | 2014 | 2280 | 0.020 |
Why?
|
Proteins | 2 | 2014 | 6032 | 0.020 |
Why?
|
Tibia | 1 | 2014 | 1070 | 0.020 |
Why?
|
Memory | 1 | 2017 | 2193 | 0.020 |
Why?
|
Schools | 1 | 2015 | 1489 | 0.020 |
Why?
|
Behavior Therapy | 1 | 2012 | 879 | 0.020 |
Why?
|
Population Surveillance | 1 | 2016 | 2598 | 0.020 |
Why?
|
Smoking Cessation | 1 | 2017 | 2057 | 0.020 |
Why?
|
Disclosure | 1 | 2010 | 748 | 0.010 |
Why?
|
Genetic Association Studies | 1 | 2013 | 2735 | 0.010 |
Why?
|
Self Report | 1 | 2015 | 3725 | 0.010 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2012 | 2199 | 0.010 |
Why?
|
Radiography | 1 | 2014 | 6965 | 0.010 |
Why?
|
Patient Acceptance of Health Care | 1 | 2016 | 3206 | 0.010 |
Why?
|
Alleles | 1 | 2013 | 6864 | 0.010 |
Why?
|
Data Collection | 1 | 2010 | 3322 | 0.010 |
Why?
|
Caregivers | 1 | 2013 | 2238 | 0.010 |
Why?
|
Massachusetts | 1 | 2014 | 8833 | 0.010 |
Why?
|
Bone Density | 1 | 2014 | 3551 | 0.010 |
Why?
|
Veterans | 1 | 2013 | 2649 | 0.010 |
Why?
|
Models, Biological | 1 | 2012 | 9469 | 0.010 |
Why?
|
Prospective Studies | 1 | 2017 | 54423 | 0.010 |
Why?
|
Pandemics | 1 | 2012 | 8656 | 0.010 |
Why?
|
Mental Disorders | 1 | 2012 | 6845 | 0.010 |
Why?
|
Infant | 1 | 2012 | 36193 | 0.010 |
Why?
|
Child, Preschool | 1 | 2012 | 42232 | 0.010 |
Why?
|
Animals | 1 | 2015 | 168475 | 0.000 |
Why?
|